Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| kitty2 | Other Identifier | Mexican Institute of Social Security |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.
Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma whose are treated with cytoreductive therapy and stem cell transplant.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| zoledronic acid or not zoledronic acid | patients with multiple myeloma will be treated with cytoreductive therapy following by zoledronic acid or not. |
| |
| zoledronic acid or not zoledronic acid | patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid |
| |
| zoledronic acid | Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| zoledronic acid | Drug | zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years |
|
| Measure | Description | Time Frame |
|---|---|---|
| progression-free disease and overall toxicity in myeloma multiple | In patients treated with cytoreductive therapy following by stem cell transplant and that received zoledronic acid by 2 years,they were evaluable for assess antitumor effect of zoledronic acid | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| skeletal event | evaluate the number of skeletal events in patients with multiple myeloma that received zoledronic acid | 3 years |
Not provided
Inclusion Criteria:
Diagnosis of multiple myeloma No previous treatment Symptomatic High risk (ISS) or stage III ( Durie-Salmon) No severe comorbidities -
Exclusion Criteria:
Pregnancy HIV + Refuse treatment
-
Not provided
Not provided
Patients with multiple myeloma previously untreated
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Agustin Aviles, MD | Instituto Mexicano del Seguro Social | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tertiary reference oncology center | Mexico City | Mexico City | 06725 | Mexico |
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077211 | Zoledronic Acid |
| ID | Term |
|---|---|
| D004164 | Diphosphonates |
| D063065 | Organophosphonates |
| D009943 | Organophosphorus Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D007093 |
| Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |